Sarepta Therapeutics will file an application with the Food and Drug Administration by the end of 2018 seeking accelerated approval for its second drug to treat Duchenne muscular dystrophy, a rare, inherited, muscle-wasting disease.
In an announcement Monday, the company, based in Cambridge, Mass., said the decision to seek a rapid approval of its drug, called golodirsen, was made after receiving a report last week that summarized a meeting with FDA officials held in February.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
Hey.
My son is 10 yrs old having exon deletion 48-52. currently he is taking deflxacort 18mg 10 days on/off.
Kindly guide me latest treatement/research update status.
Regards
Rajiv behl
919839845710
Jaipur.India
You should email the patient advocacy team at Sarepta, Siobhan SFitzgerald@sarepta.com and Allison ACraney@sarepta.com, for more information on research and development.
Hi Rajiv our patient centered team is here for you and your son. 1-844-4PTC-CARES. Please also visit our patient website http://www.PTCCares.com